AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26786240 — intervention group
Group type: EXPERIMENTAL
Intervention: CALMA-plus intervention
Number of subjects: 404
Study 26786240 — intervention group
Group type: COMPARATOR
Intervention: CALMA-only intervention
Number of subjects: 404
Study 24729133 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys' beliefs about forced sex
Number of subjects: 764
Study 24729133 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys' sexual activity
Number of subjects: 764
Study 24729133 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls' sexual activity
Number of subjects: 764
Study 24729133 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys' sexual debut
Number of subjects: 764
Study 24729133 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of peers regarding forced sex
Number of subjects: 764
Study 24729133 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge about health and legal consequences of forced sex
Number of subjects: 764
Study 24729133 — intervention group
Group type: EXPERIMENTAL
Intervention: Sociocognitive items (self-efficacy and behavioral intention)
Number of subjects: 764
Study 23079168 — intervention group
Group type: EXPERIMENTAL
Intervention: Just/Us Facebook page intervention
Number of subjects: 1578
Study 20354939 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided fine-needle aspiration (EUS-FNA)
Number of subjects: 40
Study 20354939 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided trucut biopsy (EUS-TCB)
Number of subjects: 40
Study 17267782 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking wine (2-3 glasses of wine, 4 ounces each) per night, increased to binge drinking (32-ounce bottle of wine) on several nights in the past month.
Number of subjects: 1
Study 15614570 — intervention group
Group type: EXPERIMENTAL
Intervention: Otovowen (alternative treatment)
Number of subjects: 390
Study 15614570 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (control)
Number of subjects: 390
Study 12141372 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead workers (intervention group)
Number of subjects: 29
Study 12141372 — intervention group
Group type: COMPARATOR
Intervention: Control group (14 healthy female workers at a textile factory)
Number of subjects: 29
Study 10816747 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-treated Olyset Net mosquito nets
Number of subjects: 163
Study 10816747 — intervention group
Group type: COMPARATOR
Intervention: Non-user group (no mosquito nets)
Number of subjects: 163
Study 7503204 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol 800 micrograms administered 3 days after methotrexate 50 mg/m2 intramuscularly (group 1)
Number of subjects: 86
Study 7503204 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol 800 micrograms administered 7 days after methotrexate 50 mg/m2 intramuscularly (group 2)
Number of subjects: 86
Study 7503204 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal bleeding duration in group 1
Number of subjects: 86
Study 7503204 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal bleeding duration in group 2
Number of subjects: 86
Study 7503204 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to human chorionic gonadotropin-beta level < or = 25 IU/L in group 1
Number of subjects: 86
Study 7503204 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to human chorionic gonadotropin-beta level < or = 25 IU/L in group 2
Number of subjects: 86
Study 7503204 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment failures in group 1
Number of subjects: 86
Study 7503204 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment failure in group 2
Number of subjects: 86
Study 2188753 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 g methylprednisolone (steroid) infused intravenously 2‐24 hours before planned PTCA
Number of subjects: 915
Study 2188753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 915
Study 6792956 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (cromolyn) 40 mg
Number of subjects: 6
Study 6792956 — intervention group
Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 6
Study 30975206 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention: linking nebuliser use with data recording and transfer capability to a software platform, and behavioural strategies to support self‐management delivered by trained interventionists
Number of subjects: 64
Study 30975206 — intervention group
Group type: COMPARATOR
Intervention: Control: typically face‐to‐face meetings every 3 months with CF team
Number of subjects: 64
Study 30012390 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Tai Chi (MTC)
Number of subjects: 60
Study 30012390 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 27445609 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle tip position (midline)
Number of subjects: 210
Study 27445609 — intervention group
Group type: COMPARATOR
Intervention: Needle tip position (lateral)
Number of subjects: 210
Study 27445609 — intervention group
Group type: COMPARATOR
Intervention: Bevel direction (ventral or dorsal)
Number of subjects: 210
Study 27445609 — intervention group
Group type: COMPARATOR
Intervention: Needle position (middle or lateral)
Number of subjects: 210
Study 27445609 — intervention group
Group type: COMPARATOR
Intervention: History of lumbar spine surgery
Number of subjects: 210
Study 23846165 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT, 5 min, 100 kcal)
Number of subjects: 42
Study 23846165 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Aerobic Training (HIAT, 13 min, 180 kcal)
Number of subjects: 42
Study 23846165 — intervention group
Group type: COMPARATOR
Intervention: Continuous Aerobic Training (CAT, 40 min, 360 kcal)
Number of subjects: 42
Study 22244840 — intervention group
Group type: EXPERIMENTAL
Intervention: PDL + imiquimod 5% cream
Number of subjects: 24
Study 22244840 — intervention group
Group type: COMPARATOR
Intervention: PDL + placebo
Number of subjects: 24
Study 19476833 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed loop control
Number of subjects: 45
Study 19476833 — intervention group
Group type: COMPARATOR
Intervention: Clinician control
Number of subjects: 45
Study 17803845 — intervention group
Group type: COMPARATOR
Intervention: Terazosin 2 mg once daily for six weeks
Number of subjects: 69
Study 17803845 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin 2 mg once daily and tolterodine 2 mg twice daily for six weeks
Number of subjects: 69
Study 15280079 — intervention group
Group type: EXPERIMENTAL
Intervention: ACh (Acetylcholine) delivered via intradermal microdialysis
Number of subjects: 28
Study 15280079 — intervention group
Group type: COMPARATOR
Intervention: L-NAME (5 mM) delivered simultaneously via the dialysis probe
Number of subjects: 28
Study 15280079 — intervention group
Group type: EXPERIMENTAL
Intervention: ACh at concentrations >= 6.25 mM
Number of subjects: 28
Study 15280079 — intervention group
Group type: EXPERIMENTAL
Intervention: C-fiber blockade
Number of subjects: 28
Study 15280079 — intervention group
Group type: COMPARATOR
Intervention: H1 receptor antagonist levocetirizine
Number of subjects: 28
Study 15280079 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate histamine levels
Number of subjects: 28
Study 11564053 — intervention group
Group type: EXPERIMENTAL
Intervention: Target concentration intervention (TCI)
Number of subjects: 0
Study 11564053 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic drug monitoring (TDM)
Number of subjects: 0
Study 9577302 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid test meal
Number of subjects: 8
Study 9577302 — intervention group
Group type: COMPARATOR
Intervention: Liquid test meal
Number of subjects: 8
Study 7931483 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen J (vincristine, dactinomycin, doxorubicin)
Number of subjects: 72
Study 7931483 — intervention group
Group type: COMPARATOR
Intervention: Regimen DD-RT (vincristine, dactinomycin, doxorubicin without cyclophosphamide)
Number of subjects: 72
Study 3308388 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcarnitine for 1 month
Number of subjects: 24
Study 3308388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 3308388 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcarnitine
Number of subjects: 24
Study 31522134 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (handgrip and isometric exercises)
Number of subjects: 208
Study 31522134 — intervention group
Group type: COMPARATOR
Intervention: Healthy-diet group
Number of subjects: 208
Study 31522134 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 208
Study 29553112 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF)
Number of subjects: 45
Study 29553112 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF)
Number of subjects: 45
Study 28785149 — intervention group
Group type: EXPERIMENTAL
Intervention: ESWL + ERCP
Number of subjects: 0
Study 28785149 — intervention group
Group type: COMPARATOR
Intervention: ERCP only
Number of subjects: 0
Study 26299227 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsening heart failure (WHF) during hospitalization
Number of subjects: 7141
Study 24565713 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) 400 μg once daily (QD) in the evening
Number of subjects: 0
Study 24565713 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast sodium (ML) 10 mg QD pm
Number of subjects: 0
Study 24565713 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) 200 μg QD pm
Number of subjects: 0
Study 24565713 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 250 μg twice daily
Number of subjects: 0
Study 24565713 — intervention group
Group type: COMPARATOR
Intervention: Mometasone furoate (MF) 400 μg
Number of subjects: 0
Study 22005283 — intervention group
Group type: COMPARATOR
Intervention: MeDiet+Nuts
Number of subjects: 243
Study 22005283 — intervention group
Group type: COMPARATOR
Intervention: MeDiet
Number of subjects: 243
Study 22005283 — intervention group
Group type: COMPARATOR
Intervention: MeDiet+VOO
Number of subjects: 243
Study 22005283 — intervention group
Group type: COMPARATOR
Intervention: Control (low-fat diet)
Number of subjects: 243
Study 22005283 — intervention group
Group type: COMPARATOR
Intervention: MeDiet+Nuts (among participants with prevalent depression)
Number of subjects: 243
Study 19055292 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy
Number of subjects: 0
Study 14514498 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 246
Study 14514498 — intervention group
Group type: COMPARATOR
Intervention: Mirtazapine
Number of subjects: 246
Study 14514498 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6 genotype
Number of subjects: 246
Study 10450447 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (35 mg/kg)
Number of subjects: 239
Study 10450447 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (sulfadoxine, 25 mg/kg)
Number of subjects: 239
Study 10450447 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine
Number of subjects: 239
Study 10450447 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine
Number of subjects: 239
Study 7773579 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 0
Study 7773579 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate
Number of subjects: 0
Study 7773579 — intervention group
Group type: COMPARATOR
Intervention: Pentoxifylline, cyproheptadine, hydrazine sulfate
Number of subjects: 0
Study 2193477 — intervention group
Group type: EXPERIMENTAL
Intervention: Methicillin antibiotic prophylaxis
Number of subjects: 185
Study 2193477 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (Control)
Number of subjects: 185
Study 638981 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate lymphadenectomy
Number of subjects: 173
Study 638981 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed lymphadenectomy (3 months)
Number of subjects: 173
Study 638981 — intervention group
Group type: COMPARATOR
Intervention: No lymphadenectomy
Number of subjects: 173
Study 638981 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective lymphadenectomy (overall)
Number of subjects: 173
Study 638981 — intervention group
Group type: EXPERIMENTAL
Intervention: Age greater than 60 years
Number of subjects: 173
Study 638981 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasiveness (level 4 or 5)
Number of subjects: 173
Study 638981 — intervention group
Group type: EXPERIMENTAL
Intervention: Thickness greater than 1.5 mm
Number of subjects: 173
Study 31961446 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) 5%
Number of subjects: 624
Study 31961446 — intervention group
Group type: COMPARATOR
Intervention: imiquimod (IMQ) 5%
Number of subjects: 624
Study 31961446 — intervention group
Group type: COMPARATOR
Intervention: ingenol mebutate (IM) 0.015%
Number of subjects: 624
Study 31961446 — intervention group
Group type: COMPARATOR
Intervention: methyl aminolaevulinate photodynamic therapy (MAL-PDT)
Number of subjects: 624
Study 31526255 — intervention group
Group type: EXPERIMENTAL
Intervention: Convolutional Neural Networks (CNNs) for VF detection
Number of subjects: 12742
Study 31526255 — intervention group
Group type: EXPERIMENTAL
Intervention: CNN-identified VFs
Number of subjects: 12742
Study 31526255 — intervention group
Group type: COMPARATOR
Intervention: Expert reader-detected VFs
Number of subjects: 12742
Study 29021116 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-based integrated smoking cessation and alcohol intervention; tailored mobile phone text messages for 3 months, including feedback on alcohol consumption.
Number of subjects: 1471
Study 29021116 — intervention group
Group type: COMPARATOR
Intervention: Smoking cessation only intervention; tailored mobile phone text messages for 3 months.
Number of subjects: 1471
Study 25527482 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor physical therapy (PT)
Number of subjects: 29
Study 25527482 — intervention group
Group type: EXPERIMENTAL
Intervention: Levator-directed trigger-point injections (LTPI)
Number of subjects: 29
Study 25527482 — intervention group
Group type: COMPARATOR
Intervention: Comparison of PT and LTPI
Number of subjects: 29
Study 23444090 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Recovery Group (ARG)
Number of subjects: 24
Study 23444090 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive Recovery Group (PRG)
Number of subjects: 24
Study 23444090 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 24
Study 21061122 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 201
Study 21061122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 19604188 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil 0.1 microg kg(‐1) min(‐1)
Number of subjects: 130
Study 19604188 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil 0.2 microg kg(‐1) min(‐1)
Number of subjects: 130
Study 19604188 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil 0.3 microg kg(‐1) min(‐1)
Number of subjects: 130
Study 19604188 — intervention group
Group type: COMPARATOR
Intervention: Control (no remifentanil)
Number of subjects: 130
Study 17518102 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptual epenthesis in L2 arising from syllable structure restrictions of L1
Number of subjects: 0
Study 17518102 — intervention group
Group type: EXPERIMENTAL
Intervention: Syllable structure restrictions
Number of subjects: 0
Study 17518102 — intervention group
Group type: EXPERIMENTAL
Intervention: Consonantal contact restrictions
Number of subjects: 0
Study 17518102 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of co-occurrence
Number of subjects: 0
Study 17518102 — intervention group
Group type: EXPERIMENTAL
Intervention: Steriade's Perceptual-Mapping (P-Map) hypothesis
Number of subjects: 0
Study 15213034 — intervention group
Group type: EXPERIMENTAL
Intervention: Methionine intake of 16 mg.kg(‐1).d(‐1)
Number of subjects: 21
Study 15213034 — intervention group
Group type: EXPERIMENTAL
Intervention: Methionine intakes of 3, 6, 9, 13, 18, 21, and 24 mg.kg(‐1).d(‐1)
Number of subjects: 21
Study 15213034 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet devoid of cystine
Number of subjects: 21
Study 15213034 — intervention group
Group type: EXPERIMENTAL
Intervention: 24‐h [(13)C]leucine tracer infusion
Number of subjects: 21
Study 11694786 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose of Herceptin (4 mg/kg initial dose followed by 2 mg/kg i.v. weekly)
Number of subjects: 114
Study 11694786 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of Herceptin (8 mg/kg initial dose followed by 4 mg/kg i.v. weekly)
Number of subjects: 114
Study 11694786 — intervention group
Group type: EXPERIMENTAL
Intervention: Herceptin (both doses)
Number of subjects: 114
Study 11694786 — intervention group
Group type: EXPERIMENTAL
Intervention: Herceptin in IHC 3+ patients
Number of subjects: 114
Study 11694786 — intervention group
Group type: EXPERIMENTAL
Intervention: Herceptin in FISH-positive patients
Number of subjects: 114
Study 11694786 — intervention group
Group type: EXPERIMENTAL
Intervention: Herceptin in IHC 3+ patients with stable disease for > or =6 months
Number of subjects: 114
Study 9918451 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified LAR V (Drager, Germany)
Number of subjects: 20
Study 9918451 — intervention group
Group type: COMPARATOR
Intervention: Ambu Mark III bag
Number of subjects: 20
Study 8065591 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydrogesterone with transdermal estradiol
Number of subjects: 0
Study 8065591 — intervention group
Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate with transdermal estradiol
Number of subjects: 0
Study 3389318 — intervention group
Group type: EXPERIMENTAL
Intervention: Diets containing averages of 1.22‐1.67 mg/d vitamin B‐6; actual mean vitamin B‐6 content analyzed was 0.75‐0.98 mg/d.
Number of subjects: 22
Study 3389318 — intervention group
Group type: EXPERIMENTAL
Intervention: Diets analyzed to contain means of 0.75‐0.98 mg/d of vitamin B-6.
Number of subjects: 22
Study 29461420 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (400 mg) administered 15 minutes before the race and again after 5 hours if the route was not completed
Number of subjects: 20
Study 29461420 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ibuprofen)
Number of subjects: 20
Study 31511087 — intervention group
Group type: EXPERIMENTAL
Intervention: Martial arts intervention (10 sessions of 50-60 minutes each, once per week for 10 weeks)
Number of subjects: 293
Study 31511087 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 293
Study 28444658 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilazodone
Number of subjects: 56
Study 28444658 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 56
Study 25766309 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive, multimodal phonologic therapy (60 hours)
Number of subjects: 26
Study 23370367 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (arm A)
Number of subjects: 98
Study 23370367 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (arm B)
Number of subjects: 98
Study 23370367 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine and Erlotinib (arm C)
Number of subjects: 98
Study 20644965 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy (two 30‐min classical massages per week for 5 weeks)
Number of subjects: 34
Study 20644965 — intervention group
Group type: COMPARATOR
Intervention: Control group (no massage therapy)
Number of subjects: 34
Study 20644965 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 34
Study 19929995 — intervention group
Group type: EXPERIMENTAL
Intervention: Taspoglutide 8 mg
Number of subjects: 48
Study 19929995 — intervention group
Group type: EXPERIMENTAL
Intervention: Taspoglutide 30 mg
Number of subjects: 48
Study 19929995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 17722821 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 44
Study 17722821 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study 15163258 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 45
Study 15163258 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 45
Study 11212045 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (0.1 mg/kg bolus followed by infusion at 1 microg x kg(-1) x min(-1))
Number of subjects: 60
Study 11212045 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline instead of nicorandil)
Number of subjects: 60
Study 11212045 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 60
Study 11212045 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 9877016 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (100 mg PO)
Number of subjects: 15
Study 9877016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 8072994 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary health care rendered to patients with type I diabetes at district outpatient clinics of Moscow
Number of subjects: 0
Study 3288293 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (single 50 mg dose)
Number of subjects: 8
Study 3288293 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (multiple doses of 25 and 50 mg tid for 5 days)
Number of subjects: 8
Study 3288293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 29229324 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 Gy of involved-field RT (n=209)
Number of subjects: 578
Study 29229324 — intervention group
Group type: EXPERIMENTAL
Intervention: 36 Gy of involved-field RT (n=239)
Number of subjects: 578
Study 29229324 — intervention group
Group type: COMPARATOR
Intervention: No RT (n=130)
Number of subjects: 578
Study 29229324 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 578
Study 28460083 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 or 10 mg twice daily
Number of subjects: 1115
Study 24504660 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 30